All Phenotypes Cdkn2a<tm2.1Nesh> MGI Mouse

About Help FAQ

Phenotypes associated with this allele

Allele Symbol
Allele Name
Allele ID

Cdkn2a^tm2.1Nesh
targeted mutation 2.1, Norman E Sharpless
MGI:4835008

Summary

10 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Cdkn2a^tm2.1Nesh/Cdkn2a^tm2.1Nesh Kras^tm4Tyj/Kras⁺ Tg(Tyr-cre/ERT2)13Bos/0	B6J.Cg-Tg(Tyr-cre/ERT2)13Bos Cdkn2a^tm2.1Nesh Kras^tm4Tyj	MGI:5752237
cn2	Cdkn2a^tm2.1Nesh/Cdkn2a^tm2.1Nesh Nras^tm1.1Nesh/Nras^tm1.1Nesh Tg(Tyr-cre/ERT2)13Bos/0	B6J.Cg-Tg(Tyr-cre/ERT2)13Bos Nras^tm1.1Nesh Cdkn2a^tm2.1Nesh	MGI:5752235
cn3	Cdkn2a^tm2.1Nesh/Cdkn2a^tm2.1Nesh Nras^tm1.1Nesh/Nras^tm1.1Nesh Stk11^tm1.1Rdp/Stk11^tm1.1Rdp Tg(Tyr-cre/ERT2)13Bos/0	B6J.Cg-Tg(Tyr-cre/ERT2)13Bos Nras^tm1.1Nesh Cdkn2a^tm2.1Nesh Stk11^tm1.1Rdp	MGI:5752239
cn4	Cdkn2a^tm2.1Nesh/Cdkn2a^tm2.1Nesh Nras^tm1Tyj/Nras^tm1Tyj Tg(Tyr-cre/ERT2)13Bos/0	B6J.Cg-Tg(Tyr-cre/ERT2)13Bos Nras^tm1Tyj Cdkn2a^tm2.1Nesh	MGI:5752233
cn5	Cdkn2a^tm2.1Nesh/Cdkn2a^tm2.1Nesh Nras^tm1.1Nesh/Nras⁺ Tg(Tyr-cre/ERT2)13Bos/0	involves: 129 * 129S4/SvJae * 129P2/OlaHsd * C57BL/6 * FVB	MGI:6393936
cn6	Cdkn2a^tm2.1Nesh/Cdkn2a^tm2.1Nesh Ezh2^tm1.1Nesh/Ezh2⁺ Nras^tm1.1Nesh/Nras⁺ Tg(Tyr-cre/ERT2)13Bos/0	involves: 129 * 129S4/SvJae * 129P2/OlaHsd * C57BL/6 * FVB	MGI:6393935
cn7	Cdkn2a^tm2.1Nesh/Cdkn2a^tm2.1Nesh Trp53^tm1Brn/Trp53^tm1Brn Tg(Tyr-cre/ERT2)13Bos/0	involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB	MGI:4835042
cn8	Cdkn2a^tm2.1Nesh/Cdkn2a^tm2.1Nesh Kras^tm4Tyj/Kras⁺ Trp53^tm1Brn/Trp53^tm1Brn Tg(Tyr-cre/ERT2)13Bos/0	involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB	MGI:4835041
cn9	Cdkn2a^tm2.1Nesh/Cdkn2a⁺ Kras^tm4Tyj/Kras⁺ Trp53^tm1Brn/Trp53⁺ Tg(Tyr-cre/ERT2)13Bos/0	involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB	MGI:4835045
cn10	Cdkn2a^tm2.1Nesh/Cdkn2a^tm2.1Nesh Kras^tm4Tyj/Kras⁺ Tg(Tyr-cre/ERT2)13Bos/0	involves: 129S4/SvJae * C57BL/6 * FVB	MGI:4835044

Allelic Composition	Cdkn2a^tm2.1Nesh/Cdkn2a^tm2.1Nesh Kras^tm4Tyj/Kras⁺ Tg(Tyr-cre/ERT2)13Bos/0
Genetic Background	B6J.Cg-Tg(Tyr-cre/ERT2)13Bos Cdkn2a^tm2.1Nesh Kras^tm4Tyj

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdkn2a^tm2.1Nesh mutation (4 available); any Cdkn2a mutation (62 available)
Kras^tm4Tyj mutation (9 available); any Kras mutation (76 available)
Tg(Tyr-cre/ERT2)13Bos mutation (12 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

pigmentation

hyperpigmentation ( J:220627 )

• mice treated with 4-hydroxytamoxifen (4-OHT) neonatally exhibit the presence of nevi and hyperpigmented regions on the paws and tails

integument

increased cutaneous melanoma incidence ( J:220627 )

• mice treated with 4-OHT neonatally develop melanoma with 76% penetrance and a median latency of 36.3 weeks

• melanomas contain both spindle-cell and desmoplastic cell types with no overt signs of macrometastatic spread

neoplasm

increased cutaneous melanoma incidence ( J:220627 )

• mice treated with 4-OHT neonatally develop melanoma with 76% penetrance and a median latency of 36.3 weeks

• melanomas contain both spindle-cell and desmoplastic cell types with no overt signs of macrometastatic spread

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
skin melanoma		DOID:8923	OMIM:608035 OMIM:612263	J:220627

Allelic Composition	Cdkn2a^tm2.1Nesh/Cdkn2a^tm2.1Nesh Nras^tm1.1Nesh/Nras^tm1.1Nesh Tg(Tyr-cre/ERT2)13Bos/0
Genetic Background	B6J.Cg-Tg(Tyr-cre/ERT2)13Bos Nras^tm1.1Nesh Cdkn2a^tm2.1Nesh

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdkn2a^tm2.1Nesh mutation (4 available); any Cdkn2a mutation (62 available)
Nras^tm1.1Nesh mutation (2 available); any Nras mutation (44 available)
Tg(Tyr-cre/ERT2)13Bos mutation (12 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

cellular

abnormal melanocyte proliferation ( J:220627 )

• melanocytes treated with 4-hydroxytamoxifen (4-OHT) to induce cre activity exhibit decreased proliferation in culture and cease to proliferate after 2-3 passages

integument

increased cutaneous melanoma incidence ( J:220627 )

• mice treated with 4-OHT neonatally readily develop melanoma with 70% penetrance and a median latency of 26.3 weeks

• melanomas contain both spindle-cell and desmoplastic cell types with no overt signs of macrometastatic spread

pigmentation

abnormal melanocyte proliferation ( J:220627 )

• melanocytes treated with 4-hydroxytamoxifen (4-OHT) to induce cre activity exhibit decreased proliferation in culture and cease to proliferate after 2-3 passages

hyperpigmentation ( J:220627 )

• mice treated with 4-OHT neonatally exhibit the presence of nevi and hyperpigmented regions on the paws and tails

neoplasm

increased cutaneous melanoma incidence ( J:220627 )

• mice treated with 4-OHT neonatally readily develop melanoma with 70% penetrance and a median latency of 26.3 weeks

• melanomas contain both spindle-cell and desmoplastic cell types with no overt signs of macrometastatic spread

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
skin melanoma		DOID:8923	OMIM:608035 OMIM:612263	J:220627

Allelic Composition	Cdkn2a^tm2.1Nesh/Cdkn2a^tm2.1Nesh Nras^tm1.1Nesh/Nras^tm1.1Nesh Stk11^tm1.1Rdp/Stk11^tm1.1Rdp Tg(Tyr-cre/ERT2)13Bos/0
Genetic Background	B6J.Cg-Tg(Tyr-cre/ERT2)13Bos Nras^tm1.1Nesh Cdkn2a^tm2.1Nesh Stk11^tm1.1Rdp

Find Mice

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

integument

increased cutaneous melanoma incidence ( J:220627 )

• mice treated with 4-hydroxytamoxifen (4-OHT) neonatally or in adulthood exhibit enhanced nevus formation

• mice treated with 4-OHT neonatally develop melanoma with 85% penetrance and a median latency of 22.1 weeks

neoplasm

increased cutaneous melanoma incidence ( J:220627 )

• mice treated with 4-hydroxytamoxifen (4-OHT) neonatally or in adulthood exhibit enhanced nevus formation

• mice treated with 4-OHT neonatally develop melanoma with 85% penetrance and a median latency of 22.1 weeks

increased metastatic potential ( J:220627 )

• 36% of mice treated with 4-OHT neonatally that develop melanoma show macrometastatic spread to lymph nodes, lung, spleen and/or liver

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
skin melanoma		DOID:8923	OMIM:608035 OMIM:612263	J:220627

Allelic Composition	Cdkn2a^tm2.1Nesh/Cdkn2a^tm2.1Nesh Nras^tm1Tyj/Nras^tm1Tyj Tg(Tyr-cre/ERT2)13Bos/0
Genetic Background	B6J.Cg-Tg(Tyr-cre/ERT2)13Bos Nras^tm1Tyj Cdkn2a^tm2.1Nesh

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdkn2a^tm2.1Nesh mutation (4 available); any Cdkn2a mutation (62 available)
Nras^tm1Tyj mutation (1 available); any Nras mutation (44 available)
Tg(Tyr-cre/ERT2)13Bos mutation (12 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

cellular

abnormal melanocyte proliferation ( J:220627 )

• melanocytes treated with 4-hydroxytamoxifen (4-OHT) to induce cre activity exhibit decreased proliferation in culture and cease to proliferate after 2-3 passages

integument

increased cutaneous melanoma incidence ( J:220627 )

• melanoma is very rare in mice treated with 4-OHT neonatally, with 1 in 29 mice developing tumors when observed for 80 weeks

pigmentation

abnormal melanocyte proliferation ( J:220627 )

• melanocytes treated with 4-hydroxytamoxifen (4-OHT) to induce cre activity exhibit decreased proliferation in culture and cease to proliferate after 2-3 passages

hyperpigmentation ( J:220627 )

• mice treated with 4-OHT neonatally exhibit the presence of nevi and hyperpigmented regions on the paws and tails

neoplasm

increased cutaneous melanoma incidence ( J:220627 )

• melanoma is very rare in mice treated with 4-OHT neonatally, with 1 in 29 mice developing tumors when observed for 80 weeks

Allelic Composition	Cdkn2a^tm2.1Nesh/Cdkn2a^tm2.1Nesh Nras^tm1.1Nesh/Nras⁺ Tg(Tyr-cre/ERT2)13Bos/0
Genetic Background	involves: 129 * 129S4/SvJae * 129P2/OlaHsd * C57BL/6 * FVB

Find Mice

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

neoplasm

increased melanoma incidence ( J:239472 )

• tamoxifen-treated mice develop melanoma

Allelic Composition	Cdkn2a^tm2.1Nesh/Cdkn2a^tm2.1Nesh Ezh2^tm1.1Nesh/Ezh2⁺ Nras^tm1.1Nesh/Nras⁺ Tg(Tyr-cre/ERT2)13Bos/0
Genetic Background	involves: 129 * 129S4/SvJae * 129P2/OlaHsd * C57BL/6 * FVB

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdkn2a^tm2.1Nesh mutation (4 available); any Cdkn2a mutation (62 available)
Ezh2^tm1.1Nesh mutation (1 available); any Ezh2 mutation (71 available)
Nras^tm1.1Nesh mutation (2 available); any Nras mutation (44 available)
Tg(Tyr-cre/ERT2)13Bos mutation (12 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

neoplasm

increased melanoma incidence ( J:239472 )

• tamoxifen-treated mice develop melanoma similarly to conditional Nras and Cdkn2a double mutants

Allelic Composition	Cdkn2a^tm2.1Nesh/Cdkn2a^tm2.1Nesh Trp53^tm1Brn/Trp53^tm1Brn Tg(Tyr-cre/ERT2)13Bos/0
Genetic Background	involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdkn2a^tm2.1Nesh mutation (4 available); any Cdkn2a mutation (62 available)
Tg(Tyr-cre/ERT2)13Bos mutation (12 available)
Trp53^tm1Brn mutation (18 available); any Trp53 mutation (232 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

neoplasm

increased melanoma incidence ( J:164588 )

• 1 in 19 (5%) mice treated with tamoxifen neonatally develop melanomas with spindle-like morphology at a median latency of greater than 52 weeks

pigmentation

abnormal melanocyte morphology ( J:164588 )

• tamoxifen-treated mice exhibit melanocytic proliferation unlike wild-type mice

hyperpigmentation ( J:164588 )

• tamoxifen-treated mice develop pigmented macules in the paws and tail unlike wild-type mice

Allelic Composition	Cdkn2a^tm2.1Nesh/Cdkn2a^tm2.1Nesh Kras^tm4Tyj/Kras⁺ Trp53^tm1Brn/Trp53^tm1Brn Tg(Tyr-cre/ERT2)13Bos/0
Genetic Background	involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB

Find Mice

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

premature death ( J:164588 )

• all mice treated with tamoxifen neonatally die within 14 weeks of treatment due to aggressive melanomas with spindle-like morphology unlike control mice in which only one mouse develops melanoma over a period of 60 weeks

neoplasm

increased tumor growth/size ( J:164588 )

• tumor growth is more aggressive than in Cdkn2a^tm1Rdp/Cdkn2a^tm1Rdp Tg(Tyr-HRAS)60Lc mice

increased spindle cell carcinoma incidence ( J:164588 )

• tamoxifen-treated mice develop melanomas with spindle-like morphology

increased melanoma incidence ( J:164588 )

• tumors in tamoxifen-treated mice occur on the flank, ear, and tail

• the number of tumors in tamoxifen-treated mice is greater than in similarly treated Cdkn2a^tm2.1Nesh/Cdkn2a^tm2.1Nesh Kras^tm4Tyj/Kras⁺ Tg(Tyr-cre/ERT2)13Bos mice or Kras^tm4Tyj/Kras⁺ Trp53^tm1Brn/Trp53^tm1Brn Tg(Tyr-cre/ERT2)13Bos mice

• by 15 weeks, 17 of 27 adult mice treated with tamoxifen develop melanomas at the site of application and depilation

• however, no uveal tumors are observed

pigmentation

abnormal melanocyte morphology ( J:164588 )

• tamoxifen-treated mice exhibit melanocytic proliferation unlike wild-type mice

hyperpigmentation ( J:164588 )

• tamoxifen-treated mice develop pigmented macules in the paws and tail unlike wild-type mice

Allelic Composition	Cdkn2a^tm2.1Nesh/Cdkn2a⁺ Kras^tm4Tyj/Kras⁺ Trp53^tm1Brn/Trp53⁺ Tg(Tyr-cre/ERT2)13Bos/0
Genetic Background	involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB

Find Mice

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

neoplasm

increased spindle cell carcinoma incidence ( J:164588 )

• tamoxifen-treated mice develop melanomas with spindle-like morphology

increased melanoma incidence ( J:164588 )

• 3 of 7 (43%) mice treated with tamoxifen neonatally develop melanomas with spindle-like morphology at a median latency greater than 52 weeks compared with Cdkn2a^tm2.1Nesh/Cdkn2a^tm2.1Nesh Kras^tm4Tyj/Kras⁺ Trp53^tm1Brn/Trp53^tm1Brn Tg(Tyr-cre/ERT2)13Bos mice whose median latency is 14 weeks

pigmentation

abnormal melanocyte morphology ( J:164588 )

• tamoxifen-treated mice exhibit melanocytic proliferation unlike wild-type mice

hyperpigmentation ( J:164588 )

• tamoxifen-treated mice develop pigmented macules in the paws and tail unlike wild-type mice

Allelic Composition	Cdkn2a^tm2.1Nesh/Cdkn2a^tm2.1Nesh Kras^tm4Tyj/Kras⁺ Tg(Tyr-cre/ERT2)13Bos/0
Genetic Background	involves: 129S4/SvJae * C57BL/6 * FVB

Find Mice

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

neoplasm

increased spindle cell carcinoma incidence ( J:164588 )

• tamoxifen-treated mice develop melanomas with spindle-like morphology

increased melanoma incidence ( J:164588 )

• 8 of 11 (73%) mice treated with tamoxifen neonatally develop melanomas with spindle-like morphology formation at a longer latency (median latency 24 weeks) than in Cdkn2a^tm2.1Nesh/Cdkn2a^tm2.1Nesh Kras^tm4Tyj/Kras⁺ Trp53^tm1Brn/Trp53^tm1Brn Tg(Tyr-cre/ERT2)13Bos mice (median latency 14 weeks)

pigmentation

abnormal melanocyte morphology ( J:164588 )

• tamoxifen-treated mice exhibit melanocyte proliferation unlike wild-type mice

hyperpigmentation ( J:164588 )

• tamoxifen-treated mice develop pigmented macules in the paws and tail unlike wild-type mice

Contributing Projects: Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support.	last database update 04/23/2024 MGI 6.23